Go Pro
→ My top 3 AI picks for the next decade (From The Oxford Club) (Ad)tc pixel Free ARTL Stock Alerts

Artelo Biosciences (ARTL) Financials

Artelo Biosciences logo
$6.22 -0.30 (-4.60%)
As of 04:00 PM Eastern
Compare
Annual Income Statements for Artelo Biosciences

Annual Income Statements for Artelo Biosciences

This table shows Artelo Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 8/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.02 -0.03 -0.23 -2.34 -2.17 -4.66 -7.44 -10 -9.29 -9.83 -13
Consolidated Net Income / (Loss)		 -0.02 -0.03 -0.23 -2.34 -2.17 -4.66 -7.44 -10 -9.29 -9.83 -13
Net Income / (Loss) Continuing Operations		 -0.02 -0.03 -0.23 -2.34 -2.17 -4.66 -7.44 -10 -9.29 -9.83 -13
Total Pre-Tax Income 		-0.02 -0.03 -0.23 -2.34 -2.17 -4.66 -7.44 -10 -9.29 -9.83 -13
Total Operating Income		 -0.02 -0.03 -0.23 -2.34 -3.21 -4.69 -7.44 -10 -9.93 -10 -11
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 0.02 0.03 0.23 2.34 3.21 4.69 7.44 10 9.93 10 11
Selling, General & Admin Expense		 0.02 0.03 0.23 1.09 2.12 2.77 4.60 5.96 4.23 4.12 5.98
Research & Development Expense		 - - - 1.25 1.09 1.92 2.84 4.32 5.70 5.99 5.42
Total Other Income / (Expense), net		 0.00 0.00 -0.00 0.00 1.04 0.03 0.00 0.20 0.64 0.28 -1.48
Interest Expense		 - - 0.00 - - - 0.00 0.01 - 0.00 1.10
Interest & Investment Income		 - - - - - 0.00 0.00 0.00 - 0.00 0.02
Other Income / (Expense), net		 - - - - 1.04 0.03 - 0.21 - 0.28 -0.40
Income Tax Expense		 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Weighted Average Basic Shares Outstanding		 6.41M 7.64M 8.73M 1.28M 2.17M 3.71M 18.68M 2.83M 3.23M 3.28M 2.12M
Diluted Earnings per Share		 $0.00 $0.00 ($0.03) ($1.84) ($1.00) ($1.26) - - ($3.14) ($18.30) ($12.52)
Weighted Average Diluted Shares Outstanding		 6.41M 7.64M 8.73M 1.28M 2.17M 3.71M 18.68M 2.83M 2.96M 537K 1.03M
Weighted Average Basic & Diluted Shares Outstanding		 6.41M 7.64M 8.73M 10.22M 2.17M 3.71M 18.68M 2.83M 3.23M 3.28M 2.12M

Quarterly Income Statements for Artelo Biosciences

This table shows Artelo Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Total Costs & Expenses		 - - - - - 2.38 3.15 - - 2.69 2.51
Net Income / (Loss) Attributable to Common Shareholders		 -3.08 -2.48 -2.43 -1.13 -3.78 -2.37 -3.22 -3.12 -4.17 -2.96 -2.43
Consolidated Net Income / (Loss)		 -3.07 -2.48 -2.43 -1.13 -3.78 -2.37 -3.22 -3.12 -4.17 -2.96 -2.43
Net Income / (Loss) Continuing Operations		 -3.07 -2.48 -2.43 -1.13 -3.78 -2.37 -3.22 -3.15 -4.14 -2.93 -2.43
Total Pre-Tax Income 		-3.07 -2.48 -2.43 -1.13 -3.78 -2.37 -3.22 -3.12 -4.17 -2.93 -2.43
Total Operating Income		 -3.24 -2.59 -2.51 -1.20 -3.81 -2.38 -3.15 -3.09 -2.79 -2.69 -2.51
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 3.24 2.59 2.51 1.20 3.81 2.38 3.15 3.09 2.79 2.69 2.51
Selling, General & Admin Expense		 1.12 1.08 0.83 0.87 1.34 1.00 1.28 1.81 1.89 1.92 1.63
Research & Development Expense		 2.12 1.51 1.69 0.33 2.48 1.38 1.87 1.28 0.89 0.77 0.88
Total Other Income / (Expense), net		 0.17 0.11 0.08 0.06 0.03 0.01 -0.07 -0.03 -1.38 -0.27 0.08
Interest Expense		 - - 0.00 0.00 - 0.00 0.07 0.11 - 0.10 -0.04
Interest & Investment Income		 - 0.00 0.00 0.00 - 0.01 0.00 0.01 0.01 0.00 0.04
Other Income / (Expense), net		 - 0.11 0.08 0.06 0.03 0.00 0.00 0.08 - -0.15 0.00
Income Tax Expense		 - 0.00 0.00 0.00 - - 0.00 0.00 - - 0.00
Weighted Average Basic Shares Outstanding		 3.23M 3.20M 3.23M 3.23M 3.28M 3.28M 1.32M 2.02M 2.12M 2.33M 4.60M
Diluted Earnings per Share		 ($0.95) ($0.78) ($4.52) ($2.10) ($1.15) ($12.55) ($16.86) ($3.97) ($1.96) ($4.00) ($0.89)
Weighted Average Diluted Shares Outstanding		 2.96M 3.20M 538K 538K 537K 189K 191K 787K 1.03M 739K 2.71M
Weighted Average Basic & Diluted Shares Outstanding		 3.23M 3.20M 3.23M 3.23M 3.28M 3.28M 1.32M 2.02M 2.12M 2.33M 4.60M

Annual Cash Flow Statements for Artelo Biosciences

This table details how cash moves in and out of Artelo Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 8/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 0.00 -0.01 0.57 -0.24 4.09 -2.28 4.49 -4.88 -4.07 -0.48 -1.74
Net Cash From Operating Activities		 -0.01 -0.02 -0.22 -1.61 -2.79 -4.35 -6.14 -8.01 -8.21 -8.35 -8.52
Net Cash From Continuing Operating Activities		 -0.01 -0.02 -0.22 -1.61 -2.79 -4.01 8.73 -7.62 -8.21 -8.35 -8.52
Net Income / (Loss) Continuing Operations		 -0.02 -0.03 -0.23 -2.34 -2.17 -4.66 7.44 -10 -9.29 0.00 0.00
Amortization Expense		 - - 0.00 - - - - - - 0.00 0.21
Non-Cash Adjustments To Reconcile Net Income		 - - 0.00 0.29 -0.48 0.35 1.53 2.25 0.38 -9.29 -10
Changes in Operating Assets and Liabilities, net		 0.00 0.01 0.01 0.44 -0.14 0.30 -0.24 0.22 0.70 0.94 1.77
Net Cash From Investing Activities		 0.00 0.00 0.00 -0.00 -1.50 0.00 -3.44 2.96 3.51 7.77 -0.06
Net Cash From Continuing Investing Activities		 0.00 0.00 0.00 -0.00 -1.50 0.00 -3.44 2.96 3.51 7.77 -0.06
Purchase of Investments		 - - - - - - -6.10 -13 -14 -0.48 0.00
Sale of Property, Plant & Equipment		 - - - - - - - - - 0.00 0.19
Sale and/or Maturity of Investments		 - - - - - 0.00 2.66 16 17 8.25 0.00
Other Investing Activities, net		 - - - - - - - - - 0.00 -0.25
Net Cash From Financing Activities		 0.02 0.01 0.79 1.39 8.38 1.98 14 0.00 0.57 0.11 6.87
Net Cash From Continuing Financing Activities		 0.02 0.01 0.79 1.39 8.38 1.98 14 0.00 0.57 0.11 6.87
Repayment of Debt		 - - -0.04 -0.02 -0.02 -0.01 -0.01 - - 0.00 0.17
Issuance of Debt		 - 0.00 0.05 0.02 0.02 0.01 0.00 - - 0.00 0.42
Issuance of Common Equity		 0.02 - 0.77 1.39 8.38 1.98 8.10 0.00 0.57 0.11 6.15
Other Financing Activities, net		 - 0.00 - - 0.00 0.00 6.02 - - 0.00 0.13
Effect of Exchange Rate Changes		 - - 0.00 -0.01 0.00 0.08 -0.05 -0.22 0.06 -0.01 -0.02
Cash Interest Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for Artelo Biosciences

This table details how cash moves in and out of Artelo Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -12 -1.62 -0.31 3.97 -2.51 -1.59 1.32 -0.35 -1.12 9.67 -6.08
Net Cash From Operating Activities		 -2.60 -2.94 -2.06 -0.78 -2.57 -1.60 -0.51 -3.50 -2.91 -1.19 -5.03
Net Cash From Continuing Operating Activities		 -15 -2.94 -2.06 -0.28 -3.06 -1.60 -0.51 -3.50 -2.91 -1.19 -5.03
Net Income / (Loss) Continuing Operations		 -16 -2.48 -2.43 4.92 - -2.37 -3.22 5.59 - -2.96 -2.43
Consolidated Net Income / (Loss)		 -16 -2.48 -2.43 - - -2.37 -3.22 - - -2.96 -2.43
Amortization Expense		 - - - - - 0.00 0.05 0.08 0.07 0.09 0.02
Non-Cash Adjustments To Reconcile Net Income		 0.05 0.11 0.12 -5.41 -4.11 0.19 0.16 -8.36 -2.48 0.55 0.53
Changes in Operating Assets and Liabilities, net		 0.42 -0.57 0.25 0.21 1.04 0.58 2.50 -0.82 -0.50 1.13 -3.16
Net Cash From Financing Activities		 0.03 0.06 - - 0.06 0.00 1.82 3.44 1.61 11 -1.06
Net Cash From Continuing Financing Activities		 0.03 0.06 - - 0.06 0.00 1.82 3.44 1.61 11 -1.06
Issuance of Common Equity		 0.03 0.06 - - 0.06 0.00 1.08 3.31 1.76 10 0.18
Other Financing Activities, net		 - - - - - 0.00 - - - 0.23 0.00
Effect of Exchange Rate Changes		 -0.00 -0.00 -0.00 - - 0.01 0.02 -0.04 -0.00 0.00 0.02

Annual Balance Sheets for Artelo Biosciences

This table presents Artelo Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.02 0.00 0.57 0.40 6.48 4.38 28 20 13 4.70 2.80
Total Current Assets		 0.02 0.00 0.57 0.40 4.44 2.34 25 18 11 2.56 0.70
Cash & Equivalents		 0.02 0.00 0.57 0.34 4.42 2.14 12 6.89 2.82 2.34 0.60
Prepaid Expenses		 - - 0.00 0.04 0.02 0.20 0.50 0.79 0.55 0.22 0.10
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 2.04 2.04 3.64 2.10 2.06 2.14 2.11
Intangible Assets		 - - - - 2.04 2.04 2.04 2.04 2.04 2.04 2.04
Other Noncurrent Operating Assets		 - - - - - - 1.60 0.06 0.02 0.10 0.07
Total Liabilities & Shareholders' Equity		 0.02 0.00 0.57 0.40 6.48 4.38 28 20 13 4.70 2.80
Total Liabilities		 0.00 0.02 0.03 0.53 1.02 0.50 1.08 1.02 1.29 1.84 4.07
Total Current Liabilities		 0.00 0.02 0.03 0.53 1.02 0.50 1.03 1.00 1.29 1.77 4.04
Short-Term Debt		 - - - - - - - - - 0.00 0.61
Accounts Payable		 0.00 0.02 0.03 0.53 0.35 0.50 1.00 0.91 1.24 1.68 3.04
Accrued Expenses		 - - - - - - - - - 0.00 0.01
Other Current Liabilities		 - - - - 0.67 - 0.03 0.09 0.05 0.10 0.39
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.00 0.00 0.06 0.02 0.00 0.07 0.03
Other Noncurrent Operating Liabilities		 - - - - - - 0.06 0.02 0.00 0.07 0.03
Total Equity & Noncontrolling Interests		 0.02 -0.01 0.54 -0.13 5.46 3.88 27 19 12 2.86 -1.27
Total Preferred & Common Equity		 0.02 -0.01 0.54 -0.13 5.46 3.88 27 19 12 2.86 -1.27
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 0.02 -0.01 0.54 -0.13 5.46 3.88 27 19 12 2.86 -1.27
Common Stock		 0.05 0.05 0.84 2.52 10 13 48 51 52 53 62
Retained Earnings		 -0.03 -0.06 -0.30 -2.64 -4.81 -9.47 -21 -31 -40 -50 -63
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 -0.01 -0.01 0.06 -0.02 -0.25 -0.20 -0.20 -0.27

Quarterly Balance Sheets for Artelo Biosciences

This table presents Artelo Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 15 10 8.33 7.14 3.52 4.36 4.27 13 6.46
Total Current Assets		 13 8.19 6.17 4.99 1.38 2.23 1.83 10 4.37
Cash & Equivalents		 2.64 1.20 0.88 4.36 0.75 2.07 1.72 10 4.20
Prepaid Expenses		 0.56 0.58 0.57 0.13 0.21 0.17 0.11 0.15 0.17
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 2.07 2.17 2.16 2.15 2.13 2.12 2.44 2.10 2.09
Intangible Assets		 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.04 2.04
Other Noncurrent Operating Assets		 0.03 0.13 0.12 0.11 0.09 0.09 0.40 0.06 0.05
Total Liabilities & Shareholders' Equity		 15 10 8.33 7.14 3.52 4.36 4.27 13 6.46
Total Liabilities		 0.92 0.82 1.03 0.78 2.86 5.76 4.90 5.85 1.46
Total Current Liabilities		 0.92 0.72 0.94 0.70 2.80 5.71 4.86 5.83 1.46
Short-Term Debt		 - - - - - - 0.88 0.67 0.00
Accounts Payable		 0.84 0.61 0.86 0.63 2.51 4.84 3.87 4.04 1.30
Accrued Expenses		 - - - - - 0.02 0.05 0.03 0.00
Other Current Liabilities		 0.08 0.11 0.08 0.07 0.30 0.85 0.07 1.09 0.15
Total Noncurrent Liabilities		 0.00 0.10 0.09 0.08 0.06 0.05 0.04 0.02 0.01
Other Noncurrent Operating Liabilities		 0.00 0.10 0.09 0.08 0.06 0.05 0.04 0.02 0.01
Total Equity & Noncontrolling Interests		 15 9.54 7.30 6.36 0.65 -1.41 -0.63 6.67 5.00
Total Preferred & Common Equity		 15 9.54 7.30 6.36 0.65 -1.41 -0.63 6.67 5.00
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 15 9.54 7.30 6.36 0.65 -1.41 -0.63 6.67 5.00
Common Stock		 52 53 53 53 53 55 58 73 74
Retained Earnings		 -37 -43 -45 -46 -53 -56 -59 -66 -68
Accumulated Other Comprehensive Income / (Loss)		 -0.20 -0.20 -0.20 -0.22 -0.23 -0.30 -0.28 -0.25 -0.24

Annual Metrics And Ratios for Artelo Biosciences

This table displays calculated financial ratios and metrics derived from Artelo Biosciences' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 8/31/2015 8/31/2016 8/31/2017 8/31/2018 8/31/2019 8/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.18% -94.80% -682.04% -909.18% 7.32% -115.78% -100.96% -7.04% 1.49% 1.05% -17.96%
EBIT Growth		 0.18% -94.80% -684.07% -906.70% 7.31% -115.73% -100.96% -7.04% 1.49% 1.05% -20.08%
NOPAT Growth		 0.18% -94.80% -684.07% -906.70% -36.96% -46.00% -100.96% -9.24% 3.47% -1.79% -12.82%
Net Income Growth		 0.18% -94.80% -691.14% -897.70% 7.31% -114.30% -102.08% -35.58% 7.87% -5.78% -31.07%
EPS Growth		 0.00% 0.00% 0.00% -897.70% 45.65% 0.00% 0.00% 0.00% 0.00% -5.78% 31.58%
Operating Cash Flow Growth		 11.57% -36.94% -1,072.70% -642.56% -73.46% -55.66% -41.27% -30.40% -2.49% -1.74% -2.04%
Free Cash Flow Firm Growth		 0.00% 42.53% -2,869.69% -684.74% -214.08% -5.85% -99.02% 23.96% -6.48% 2.16% 1.02%
Invested Capital Growth		 0.00% -900.00% -60.66% -1,590.88% 319.57% 67.08% 76.23% -38.77% -29.09% -60.86% -342.58%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.87% -91.00% -32.46% 26.28% -4.75% -30.38% -25.11% -3.92% -3.04% 6.75%
EBIT Q/Q Growth		 0.00% 0.87% -91.49% -32.48% 26.27% -4.74% -30.38% -25.11% -3.92% -3.04% 5.08%
NOPAT Q/Q Growth		 0.00% 0.87% -91.49% -32.48% -8.94% -1.61% -30.38% -27.68% 2.32% -6.00% 8.25%
Net Income Q/Q Growth		 0.00% 0.87% -90.21% -32.47% -7.71% -4.06% -30.30% -26.21% 2.78% -7.73% -3.11%
EPS Q/Q Growth		 0.00% 0.00% -200.00% -32.47% -2.04% 0.00% 0.00% 0.00% 5.42% -7.73% -102.26%
Operating Cash Flow Q/Q Growth		 -20.83% 13.36% -268.35% -28.38% -24.37% 4.16% -7.22% -14.38% -3.83% 0.35% -4.21%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -171.25% -5.56% -61.38% 25.35% -59.10% 2.90% 0.05% 3.04% -8.49%
Invested Capital Q/Q Growth		 0.00% -33.16% 91.05% -13.19% 782.13% -10.94% 63.88% -22.73% -22.64% -65.49% 14.82%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 99.36% 99.92% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.90% 100.00% 100.00% 99.98% 99.98% 100.03% 93.54% 100.00% 109.15%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -101.54% -3,985.23% -88.46% -1,143.55% -81.57% -99.72% -60.61% -43.30% -59.63% -134.52% -1,625.11%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% -362.14% -287.05% -330.60% -244.39% -400.94% -679.52% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -101.54% -3,985.23% -88.46% -1,143.55% -81.57% -99.72% -60.61% -43.30% -59.63% -134.52% -1,625.11%
Return on Equity Simple (ROE_SIMPLE)		 -99.68% 215.14% -43.11% 1,736.25% -39.77% -120.13% -34.63% -51.97% -79.04% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.01 -0.02 -0.16 -1.64 -2.25 -3.28 -6.59 -7.20 -6.95 -7.08 -7.98
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -28.79% -86.40% -24.96% -154.48% 3.13% -41.88% -21.44% -13.84% -16.72% -43.10% -421.18%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - -24.26% - -59.15% -247.66% 1,211.35%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -0.02 -0.03 -0.23 -2.34 -2.17 -4.69 -9.42 -10 -9.93 -9.83 -12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.02 -0.03 -0.23 -2.34 -2.17 -4.69 -9.42 -10 -9.93 -9.83 -12
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 1.21 1.11 0.81 0.43 0.38 1.20 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 1.94 2.35 0.87 0.48 0.46 4.18 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 2.13 1.25 0.00 0.00 0.00 2.09 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.48
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.06 -13.84 -1.09 -2.22 -0.89 -0.70 -0.85 -0.89 -0.90 -0.87 -1.47
Leverage Ratio		 1.06 13.84 1.09 2.37 1.29 1.16 1.05 1.05 1.07 1.21 4.73
Compound Leverage Factor		 1.06 13.84 1.10 2.37 1.29 1.16 1.05 1.05 1.00 1.21 5.16
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -93.02%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -93.02%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 193.02%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.05
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.08
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 0.00 -14.78 2.39 -0.89 11.02 2.11 -3.87 -20.53 -46.47
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.79 0.21 19.51 0.75 4.35 4.66 23.96 18.36 8.51 1.44 0.17
Quick Ratio		 9.79 0.21 19.46 0.68 4.33 4.28 23.48 17.57 8.08 1.32 0.15
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.01 -0.01 -0.15 -1.20 -3.76 -3.98 -7.91 -6.02 -6.41 -6.27 -6.20
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -190,534.91% -405,912.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -72.57 0.00 0.00 0.00 0.00 -1,203.38 0.00 0.00 -5.63
Operating Cash Flow to Interest Expense		 0.00 0.00 -103.25 0.00 0.00 0.00 0.00 -1,601.60 0.00 0.00 -7.73
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -103.25 0.00 0.00 0.00 0.00 -1,601.60 0.00 0.00 -7.56
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.00 -0.02 -0.03 -0.47 1.04 1.73 3.05 1.87 1.33 0.52 -1.26
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.00 -0.02 -0.01 -0.44 1.51 0.70 1.32 -1.18 -0.54 -0.81 -1.78
Enterprise Value (EV)		 0.00 0.00 0.00 12 2.21 2.17 -2.16 -9.28 -5.96 1.08 2.48
Market Capitalization		 0.00 0.00 0.00 13 6.63 4.32 22 8.25 4.46 3.42 2.46
Book Value per Share		 $0.00 $0.00 $0.06 ($0.01) $1.61 $0.86 $0.64 $6.79 $3.69 $0.89 ($0.63)
Tangible Book Value per Share		 $0.00 $0.00 $0.06 ($0.01) $1.01 $0.41 $0.59 $6.08 $3.05 $0.25 ($1.64)
Total Capital		 0.02 -0.01 0.54 -0.13 5.46 3.88 27 19 12 2.86 -0.66
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.61
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.02 -0.00 -0.57 -0.34 -4.42 -2.14 -24 -18 -10 -2.34 0.01
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.00 -0.02 -0.03 -0.47 -1.00 -0.31 -0.53 -0.21 -0.74 -1.55 -3.34
Debt-free Net Working Capital (DFNWC)		 0.02 -0.01 0.54 -0.14 3.42 1.84 24 17 9.69 0.79 -2.74
Net Working Capital (NWC)		 0.02 -0.01 0.54 -0.14 3.42 1.84 24 17 9.69 0.79 -3.35
Net Nonoperating Expense (NNE)		 0.00 0.01 0.07 0.70 -0.07 1.37 2.82 2.88 2.34 2.75 4.90
Net Nonoperating Obligations (NNO)		 -0.02 -0.00 -0.57 -0.34 -4.42 -2.14 -24 -18 -10 -2.34 0.01
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.21
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($3.60) ($27.60) ($15.00) ($18.90) ($6.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 53.39K 63.67K 94.60K 116.69K 144.83K 1.01M 2.82M 2.86M 3.23M 546.84K 2.12M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($3.60) ($27.60) ($21.90) ($18.90) ($6.00) $0.00 $0.00 ($18.30) ($12.52)
Adjusted Weighted Average Diluted Shares Outstanding		 53.39K 63.67K 94.60K 116.69K 144.83K 1.01M 2.82M 2.86M 3.23M 537.17K 1.03M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($3.60) ($27.60) $0.00 ($18.90) ($6.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 53.39K 63.67K 72.77K 85.17K 228.42K 247.18K 1.25M 2.83M 3.23M 546.84K 2.12M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.01 -0.02 -0.16 -1.64 -2.25 -3.28 -6.59 -7.20 -6.95 -7.08 -7.98
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -110.85 0.00 0.00 0.00 0.00 -2,016.00 0.00 0.00 -10.71
NOPAT to Interest Expense		 0.00 0.00 -77.60 0.00 0.00 0.00 0.00 -1,440.18 0.00 0.00 -7.24
EBIT Less CapEx to Interest Expense		 0.00 0.00 -110.85 0.00 0.00 0.00 0.00 -2,016.00 0.00 0.00 -10.54
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -77.60 0.00 0.00 0.00 0.00 -1,440.18 0.00 0.00 -7.07
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Artelo Biosciences

This table displays calculated financial ratios and metrics derived from Artelo Biosciences' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 3,188,959.00 3,227,700.00 3,227,700.00 3,227,700.00 3,227,700.00 3,281,032.00 3,281,032.00 1,321,552.00 - 2,124,772.00 2,333,540.00
DEI Adjusted Shares Outstanding		 531,493.00 537,950.00 537,950.00 537,950.00 537,950.00 182,280.00 182,280.00 1,321,552.00 - 708,257.00 2,333,540.00
DEI Earnings Per Adjusted Shares Outstanding		 -5.79 -4.62 -4.52 -2.10 -7.00 -13.01 -17.67 -2.36 - -4.18 -1.04
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 2.97% -14.53% -52.16% 53.78% -16.60% 4.19% -27.25% -158.92% 28.14% -15.51% 19.77%
EBIT Growth		 2.97% -14.53% -52.16% 53.78% -16.60% 4.19% -29.47% -166.25% 26.26% -19.17% 20.48%
NOPAT Growth		 6.79% -12.96% -40.81% 54.28% -17.65% 8.11% -25.40% -158.49% 26.92% -13.03% 20.48%
Net Income Growth		 7.97% -14.53% -52.16% 53.78% -22.94% 4.47% -32.39% -175.62% -10.27% -24.70% 24.65%
EPS Growth		 24.60% -2.63% 0.00% 53.78% -22.94% 4.47% -32.39% -89.05% -70.43% 68.13% 94.72%
Operating Cash Flow Growth		 -13.21% -34.58% -27.11% 56.83% 1.12% 45.72% 75.08% -349.61% -13.40% 25.42% -879.18%
Free Cash Flow Firm Growth		 -38.01% -6.37% -16.70% 44.25% -7.97% 122.50% 351.53% 230.84% 90.75% 167.65% -303.26%
Invested Capital Growth		 -29.09% -10.53% -25.47% -12.25% -60.86% -104.88% -304.60% -198.27% -342.58% -3,018.09% 123.01%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -32.30% 23.36% 2.01% 53.47% -233.75% 37.03% -30.14% 6.95% 7.37% -1.22% 9.61%
EBIT Q/Q Growth		 -32.30% 23.36% 2.01% 53.47% -233.75% 37.03% -32.41% 4.32% 7.56% -1.76% 11.64%
NOPAT Q/Q Growth		 -23.95% 20.09% 2.97% 52.43% -219.00% 37.59% -32.41% 1.94% 9.81% 3.48% 6.84%
Net Income Q/Q Growth		 -25.48% 19.20% 2.01% 53.47% -233.75% 37.22% -35.79% 3.14% -33.53% 29.00% 17.95%
EPS Q/Q Growth		 -14.46% 17.89% 2.01% 53.47% -233.75% 37.22% -35.79% 29.23% 50.63% -104.08% 77.75%
Operating Cash Flow Q/Q Growth		 -44.06% -13.33% 29.88% 62.29% -229.95% 37.79% 67.81% -580.54% 16.78% 59.09% -322.59%
Free Cash Flow Firm Q/Q Growth		 -53.41% 8.05% 25.67% 46.83% -197.11% 119.16% 730.95% -72.34% -121.01% 654.41% -731.04%
Invested Capital Q/Q Growth		 -22.64% 45.40% -11.98% -11.37% -65.49% -118.11% -3,593.62% 57.43% 14.82% -132.80% 127.26%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.82% 100.00%
Interest Burden Percent		 94.85% 100.00% 100.00% 100.00% 100.00% 99.71% 102.25% 103.52% 149.53% 103.49% 96.89%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -59.63% -70.68% -88.58% -87.12% -134.52% -190.70% -356.46% -436.14% -1,625.11% -367.70% -705.71%
Cash Return on Invested Capital (CROIC)		 -400.94% -339.55% -356.74% -401.81% -679.52% 0.00% 0.00% 0.00% 0.00% 0.00% -1,504.29%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -59.63% -70.68% -88.58% -87.12% -134.52% -190.70% -356.46% -436.14% -1,625.11% -367.70% -705.71%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -100.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -2.27 -1.81 -1.76 -0.84 -2.67 -1.67 -2.21 -2.16 -1.95 -1.88 -1.75
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.76% -5.81% -6.89% -3.34% -17.39% -16.92% -26.50% -33.59% -190.61% -20.79% -21.50%
Return On Investment Capital (ROIC_SIMPLE)		 -19.30% -19.00% -24.09% -13.15% -93.40% -255.41% 156.83% -893.51% 295.93% -25.64% -35.09%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -3.24 -2.48 -2.43 -1.13 -3.78 -2.38 -3.15 -3.01 -2.79 -2.84 -2.51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -3.24 -2.48 -2.43 -1.13 -3.78 -2.38 -3.10 -2.93 -2.72 -2.75 -2.48
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.38 0.50 0.59 0.57 1.20 4.40 0.00 0.00 0.00 0.80 0.52
Price to Tangible Book Value (P/TBV)		 0.46 0.64 0.82 0.84 4.18 0.00 0.00 0.00 0.00 1.16 0.88
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 2.09 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.38 -0.48 0.10 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.90 -0.85 -0.83 -0.85 -0.87 -0.82 -1.30 -1.00 -1.47 -1.41 -1.74
Leverage Ratio		 1.07 1.06 1.07 1.08 1.21 1.36 2.15 1.99 4.73 2.19 3.01
Compound Leverage Factor		 1.02 1.06 1.07 1.08 1.21 1.36 2.20 2.06 7.07 2.27 2.92
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 361.57% -93.02% 9.13% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 361.57% -93.02% 9.13% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -261.57% 193.02% 90.87% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.07 -0.05 -0.06 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.80 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.10 -0.08 -0.08 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.00 1.17 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.18 -2.20 -5.29 -6.10 -16.28 -23.03 -20.50 -21.75 -35.85 -7.13 -14.49
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.51 11.36 6.56 7.15 1.44 0.49 0.39 0.38 0.17 1.79 3.00
Quick Ratio		 8.08 10.55 5.96 6.97 1.32 0.27 0.36 0.35 0.15 1.76 2.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.72 -1.59 -1.18 -0.63 -1.86 0.36 2.96 0.82 -0.17 0.95 -6.02
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 41.17 7.38 0.00 9.55 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -7.14 -31.51 0.00 -11.91 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -7.14 -31.51 0.00 -11.91 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.33 1.93 1.70 1.50 0.52 -0.09 -3.47 -1.48 -1.26 -2.93 0.80
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -0.54 -0.23 -0.58 -0.21 -0.81 -2.02 -5.17 -2.98 -1.78 -2.84 4.27
Enterprise Value (EV)		 -5.96 -2.83 -1.28 -1.24 1.08 2.12 5.19 5.22 2.48 -4.23 -1.58
Market Capitalization		 4.46 4.78 4.33 3.62 3.42 2.87 7.26 6.07 2.46 5.37 2.61
Book Value per Share		 $3.69 $2.95 $2.26 $1.97 $0.89 $0.20 ($0.43) ($0.48) ($0.63) $3.14 $2.14
Tangible Book Value per Share		 $3.05 $2.32 $1.63 $1.34 $0.25 ($0.42) ($1.05) ($2.02) ($1.64) $2.18 $1.27
Total Capital		 12 9.54 7.30 6.36 2.86 0.65 -1.41 0.24 -0.66 7.34 5.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.88 0.61 0.67 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -10 -7.61 -5.60 -4.86 -2.34 -0.75 -2.07 -0.85 0.01 -9.60 -4.20
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.74 -0.14 -0.37 -0.57 -1.55 -2.17 -5.55 -3.88 -3.34 -5.01 -1.28
Debt-free Net Working Capital (DFNWC)		 9.69 7.47 5.23 4.29 0.79 -1.42 -3.48 -2.16 -2.74 5.26 2.92
Net Working Capital (NWC)		 9.69 7.47 5.23 4.29 0.79 -1.42 -3.48 -3.03 -3.35 4.59 2.92
Net Nonoperating Expense (NNE)		 0.81 0.67 0.67 0.30 1.11 0.71 1.02 0.96 2.22 1.08 0.67
Net Nonoperating Obligations (NNO)		 -10 -7.61 -5.60 -4.86 -2.34 -0.75 -2.07 -0.85 0.01 -9.60 -4.20
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.05 0.08 0.07 0.09 0.02
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.95) ($0.78) $0.00 $0.00 ($6.90) $0.00 $0.00 $0.00 ($1.96) $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 3.23M 3.23M 537.95K 537.95K 546.84K 182.28K 440.52K 2.02M 2.12M 2.33M 4.60M
Adjusted Diluted Earnings per Share		 ($0.95) ($0.78) $0.00 ($2.10) ($6.90) ($12.96) ($16.83) ($3.97) ($1.96) ($4.00) ($0.89)
Adjusted Weighted Average Diluted Shares Outstanding		 2.96M 3.23M 537.95K 538K 89.50K 182.28K 191.33K 787K 1.03M 739K 2.71M
Adjusted Basic & Diluted Earnings per Share		 ($0.95) ($0.78) $0.00 $0.00 ($6.90) $0.00 $0.00 $0.00 ($1.96) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.23M 3.20M 537.95K 537.95K 546.84K 182.28K 440.52K 2.02M 2.12M 2.33M 4.60M
Normalized Net Operating Profit after Tax (NOPAT)		 -2.27 -1.81 -1.76 -0.84 -2.67 -1.67 -2.21 -2.16 -1.95 -1.88 -1.75
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -43.75 -27.15 0.00 -28.35 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -30.63 -19.48 0.00 -18.82 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -43.75 -27.15 0.00 -28.35 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -30.63 -19.48 0.00 -18.82 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Artelo Biosciences’ latest statements show a clinical-stage biotechnology company with no reported revenue, persistent operating losses and continued reliance on external financing. The data provided spans the third quarter of 2023 through the second quarter of 2026. In Q2 2026, revenue remained zero and the company reported a net loss of $2.4 million, although the loss narrowed from $3.0 million in Q1 2026 and $3.2 million in Q2 2025.

Operating expenses also improved modestly. Q2 2026 operating expenses were $2.5 million, down from $2.7 million in Q1 2026, $3.2 million in Q2 2025 and $3.8 million in Q4 2024. Research and development spending declined to $876,000 from $1.9 million in Q2 2025, while selling, general and administrative expenses fell to $1.6 million from $1.9 million in the prior quarter. These reductions helped moderate the quarterly loss, but they may also reflect changes in development activity rather than improving operating economics.

Liquidity remains the central concern. Cash and equivalents fell from $10.3 million at the end of Q1 2026 to $4.2 million at June 30, 2026. The company used $5.0 million in operating cash during Q2 and reported a total cash decrease of $6.1 million. At the Q2 cash-burn rate, the reported cash balance alone would cover less than one quarter of operations, although actual runway will depend on spending changes and future financing.

The balance sheet has improved substantially from the negative-equity position reported in 2025. Total liabilities declined from $5.8 million in Q1 2026 to $1.5 million in Q2, and shareholders’ equity remained positive at $5.0 million. However, retained earnings were a cumulative deficit of $68.4 million, underscoring the company’s long history of losses. Capital raises have supported liquidity, but they also create potential dilution for existing shareholders.

  • Operating losses narrowed: Q2 2026 net loss improved to $2.4 million from $3.0 million in Q1 2026, $3.2 million in Q2 2025 and $4.2 million in Q4 2025.
  • Operating expenses declined: Total operating expenses fell to $2.5 million in Q2 2026, the lowest level in the supplied quarterly data since at least Q1 2024.
  • Balance-sheet solvency improved: Total liabilities dropped to $1.5 million from $5.8 million in the prior quarter, while total equity remained positive at $5.0 million.
  • Research spending became more controlled: R&D expense declined to $876,000 in Q2 2026 from $1.9 million in Q2 2025, potentially reducing near-term cash requirements.
  • Liquidity is highly dependent on financing: The company raised more than $10.0 million through common equity issuance in Q1 2026, but Q2 financing cash flow was negative $1.1 million despite $175,000 of reported equity issuance.
  • Intangible assets remained significant: Intangible assets were consistently reported at approximately $2.0 million, but their value depends on the company’s ability to advance and commercialize its development programs.
  • No revenue has been reported: Revenue and gross profit were zero in every income statement supplied, leaving the company without an operating source of cash.
  • Cash burn accelerated sharply in Q2 2026: Operating cash outflow increased to $5.0 million from $1.2 million in Q1 2026, with a $3.2 million unfavorable change in operating assets and liabilities.
  • Cash reserves declined materially: Cash and equivalents fell 59% sequentially to $4.2 million, down from $10.3 million at March 31, 2026 and $15.5 million at September 30, 2023 when cash and short-term investments are combined.
  • Shareholder dilution remains a risk: The common-stock balance increased from $52.0 million in Q3 2023 to $73.6 million in Q2 2026, while weighted-average basic shares in Q2 2026 were 4.6 million versus 1.3 million in Q2 2025.

Overall, the financial trend is mixed but risk-heavy. Artelo has reduced expenses, narrowed its quarterly loss and repaired its balance sheet through financing activity. Nevertheless, the company continues to report no revenue, substantial cumulative losses and negative operating cash flow. Unless cash usage declines materially or additional capital is raised, funding needs and potential dilution are likely to remain important considerations for investors.

09/03/26 10:40 PM ETAI Generated. May Contain Errors.

Artelo Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Artelo Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Artelo Biosciences' net income appears to be on an upward trend, with a most recent value of -$12.88 million in 2025, rising from -$15.24 thousand in 2015. The previous period was -$9.83 million in 2024. See where experts think Artelo Biosciences is headed by visiting Artelo Biosciences' forecast page.

Artelo Biosciences' total operating income in 2025 was -$11.40 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $11.40 million

Over the last 10 years, Artelo Biosciences' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Artelo Biosciences' total liabilities were at $4.07 million at the end of 2025, a 121.2% increase from 2024, and a 234,115.1% increase since 2015.

In the past 10 years, Artelo Biosciences' cash and equivalents has ranged from $3.59 thousand in 2016 to $12.16 million in 2021, and is currently $600 thousand as of their latest financial filing in 2025.

Over the last 10 years, Artelo Biosciences' book value per share changed from 0.00 in 2015 to -0.63 in 2025, a change of -28,740.9%.


Related Companies

Financial statements for NASDAQ:ARTL last updated on 8/31/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel